The administration of Nicotinamide mononucleotide(NMN) which is a key precursory metabolite of NAD+ has been reported to have remarkable therapeutic effects on age-related diseases. However systemic evaluation pertaining to the subacute toxicity of NMN remains to be determined.
Recently, the Shanghai Institute of Organic Chemistry conducted a study about the subacute toxicity of NMN in mice and beagle dogs, both of which were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 or 14 days (Figure 1).
Figure 1
In mice, NMN administrated once per day for 7 days is well tolerated with minimal deleterious effects. Upon higher dosage, they observe a slightly increased level of alanine aminotransferase, while other biomarkers remain unchanged (Figure 2).
Figure 2
Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid (Figure 3).
Figure 3
Interestingly, in mice that received higher NMN dosage, measurements of blood lipids, including total cholesterol, triglyceride, and low-density lipoprotein cholesterol, were significantly decreased which indicated that the lipid metabolic process being prominently highlighted (Figure 4).
Figure 4
Despite the administration of NMN was conducted in the short-term, it is sufficient to provide a solid foundation for the security of NMN.